PCSA (Processa Pharmaceuticals) 3-1 Month Momentum %: -24.39% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCSA Processa Pharmaceuticals Inc PCSA
28 GF Score
Price $2.08
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals 3-1 Month Momentum %?

Processa Pharmaceuticals PCSA -4.63% 28 3-1 Month Momentum % is -24.39% as of Jul. 14, 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,385 Biotechnology companies, Processa Pharmaceuticals ranks worse than 74.87% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-14), Processa Pharmaceuticals's 3-1 Month Momentum % is -24.39%.

The industry rank for Processa Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:

PCSA's 3-1 Month Momentum % is ranked worse than
74.87% of 1385 companies
in the Biotechnology industry
Industry Median: -10.59 vs PCSA: -24.39

Processa Pharmaceuticals  (NAS:PCSA) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Processa Pharmaceuticals 3-1 Month Momentum % Related Terms

PCSA vs ELAB, MBIO, DRMA: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Processa Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Processa Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's 3-1 Month Momentum % falls into.


PCSA
28GF Score
Processa Pharmaceuticals Inc PCSA
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals  (NAS:PCSA) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -24.39% mean?
Processa Pharmaceuticals (PCSA) has a 3-1 Month Momentum % of -24.39% as of Jul. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Processa Pharmaceuticals and its competitors. According to the industry distribution chart, Processa Pharmaceuticals ranks #1037 out of 1385 companies in the Biotechnology industry, placing it in the top 74.9%.
Is Processa Pharmaceuticals' 3-1 Month Momentum % too high?
Processa Pharmaceuticals' current 3-1 Month Momentum % is -24.39%. Based on the distribution chart, Processa Pharmaceuticals ranks #1037 out of 1385 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' 3-1 Month Momentum % compare to ELAB and MBIO?
According to the Biotechnology industry distribution chart, Processa Pharmaceuticals ranks #1037 out of 1385 companies for 3-1 Month Momentum %. This places Processa Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current 3-1 Month Momentum % is -24.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current 3-1 Month Momentum % of -24.39%. The current 3-1 Month Momentum % is -24.39%. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current 3-1 Month Momentum % is -24.39% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score

Get the complete analysis for PCSA

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price